Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BMS-986449 |
| Trade Name | |
| Synonyms | BMS 986449|BMS986449 |
| Drug Descriptions |
BMS-986449 is a molecular glue degrader that induces CRBN-dependent proteasomal degradation of IKZF2 (Helios) and IKZF4 (Eos) in regulatory T-cells (Treg), which potentially induces Treg reprogramming and enhances antitumor immune response (Cancer Res (2025) 85 (8_Supplement_2): ND05, NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C216970 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BMS-986449 | BMS-986449 | 0 | 1 |
| BMS-986449 + Nivolumab | BMS-986449 Nivolumab | 0 | 1 |